CSL (OTCMKTS:CSLLY) Shares Up 8.6% – Should You Buy?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s stock price was up 8.6% on Friday . The company traded as high as $26.61 and last traded at $26.03. Approximately 65,070 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 329,145 shares. The stock had previously closed at $23.96.

Analyst Ratings Changes

Several analysts have recently commented on CSLLY shares. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Monday, December 29th. Royal Bank Of Canada lowered CSL from a “moderate buy” rating to a “hold” rating in a report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

CSL Stock Up 0.9%

The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 2.46. The firm has a 50 day moving average of $49.02 and a two-hundred day moving average of $58.03.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.